Showing 1-10 of about 22 articles.

Rafael Pharmaceutical Inc.

Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”

Newark, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...

February 07, 2019

Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium

Newark, NJ, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the study plan for a Phase 3...

January 17, 2019

Rafael Pharmaceutical Inc.

EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Newark, NJ, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the European Medicines Agency...

January 10, 2019

Rafael Pharmaceutical Inc.

EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer

January 10, 2019

Rafael Pharmaceutical Inc.

UPDATED RELEASE: Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia

Newark, NJ, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of patient...

January 09, 2019

Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia

Newark, NJ, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of patient...

January 08, 2019

Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

Newark, NJ, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael”), a leader in the field of cancer metabolism, today announced that Sanjeev Luther, President & CEO of Rafael...

January 07, 2019

Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer

Newark, NJ, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a phase...

December 11, 2018

Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Newark, NJ, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation...

November 29, 2018

Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613

Newark, NJ, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Mike Stelmah as...

November 06, 2018

Showing 1-10 of about 22 articles.

Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”

Rafael Pharmaceuticals to Present Plan for Phase 3 Trial (AVENGER 500) of devimistat (CPI-613®) in Combination with Modified FOLFIRINOX as a First Line Treatment for Metastatic Pancreatic Cancer at 2019 Gastrointestinal Cancers Symposium

EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Metastatic Pancreatic Cancer

UPDATED RELEASE: Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia

Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia

Rafael Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer

Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Rafael Pharmaceuticals Appoints Vice President, Manufacturing and CMC Regulatory Affairs and Vice President of Regulatory Affairs to Strengthen Development of CPI-613

Newswire Distribution Network & Management

About Us